Skip to main content

Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study

The Original Article was published on 14 September 2021

Correction to: BMC Cancer 21, 1021 (2021)

https://doi.org/10.1186/s12885-021-08738-z

Following publication of the original article [1], the authors identified an error in the author names of Mustafa Erman, Bivas Biswas, Pongwut Danchaivijitr, Lingwu Chen and Chandrasekhar Chikatapu. The given names and family names were erroneously transposed.

Further to this, figure 1 has been updated. The line colors in “C” section for “Poor” and “Unknown” have been changed to align with Figure B and legend to match the line colors.

The author group has been updated above and the original article [1] has been corrected.

Fig. 1
figure1

Kaplan-Meier plot for PFS for (A) all patients, (B) MSKCC risk categories, and (C) IMDC risk categories (FAS)

Reference

  1. 1.

    Erman M, Biswas B, Danchaivijitr P, et al. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study. BMC Cancer. 2021;21(1):1021. https://doi.org/10.1186/s12885-021-08738-z.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ravindran Kanesvaran.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Erman, M., Biswas, B., Danchaivijitr, P. et al. Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study. BMC Cancer 21, 1191 (2021). https://doi.org/10.1186/s12885-021-08848-8

Download citation